UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000030809 |
|---|---|
| Receipt number | R000035174 |
| Scientific Title | Effects of narrow-band ultraviolet-B irradiation on gene expression of histamine H1 receptor and allergy-related cytokines in nasal mucosa of patients with allergic rhinitis. |
| Date of disclosure of the study information | 2018/02/19 |
| Last modified on | 2019/04/11 17:50:47 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Effects of narrow-band ultraviolet-B irradiation on gene expression of histamine H1 receptor and allergy-related cytokines in nasal mucosa of patients with allergic rhinitis.
Acronym
Effects of narrow-band ultraviolet-B irradiation on gene expression of histamine H1 receptor and allergy-related cytokines in nasal mucosa of patients with allergic rhinitis.
Scientific Title
Effects of narrow-band ultraviolet-B irradiation on gene expression of histamine H1 receptor and allergy-related cytokines in nasal mucosa of patients with allergic rhinitis.
Scientific Title:Acronym
Effects of narrow-band ultraviolet-B irradiation on gene expression of histamine H1 receptor and allergy-related cytokines in nasal mucosa of patients with allergic rhinitis.
Region
| Japan |
Condition
Condition
Allergic rhinitis
Classification by specialty
| Oto-rhino-laryngology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
In the present study, an attempt is made to examine the effects of intranasal irradiation with narrow-band ultraviolet-B on gene expression of histamine H1 receptor and allergy-related cytokines in nasal mucosa of patients with allergic rhinitis. After intranasal irradiation with narrow-band ultraviolet-B was given once or once a day for 3 days, changes in levels of histamine H1 receptor and allergy-related cytokine mRNAs in the nasal mucosa are examined.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Gene expression of histamine H1 receptor and allergy-related cytokines (IL-4, 5 and 9) in the nasal mucosa
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Device,equipment |
Interventions/Control_1
Intranasal irradiation of narrow-band ultraviolet-B once or once a day for 3 days
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 65 | years-old | > |
Gender
Male and Female
Key inclusion criteria
Adult patients with allergic rhinitis
Key exclusion criteria
Patients who was excluded by investigators
Target sample size
20
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Noriaki Takeda |
Organization
University of Tokushima School of Medicine
Division name
Department of Otolaryngology
Zip code
Address
3-18-15 Kuramoto, Tokushima, Japan
TEL
088-633-7169
takeda@tokushima-u.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Noriaki Takeda |
Organization
University of Tokushima School of Medicine
Division name
Department of Otolaryngology
Zip code
Address
3-18-15 Kuramoto, Tokushima, Japan
TEL
088-633-7169
Homepage URL
takeda@tokushima-u.ac.jp
Sponsor or person
Institute
University of Tokushima
Institute
Department
Personal name
Funding Source
Organization
Japan Agency of Medical Research and Development
Organization
Division
Category of Funding Organization
Japanese Governmental office
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2018 | Year | 02 | Month | 19 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2018 | Year | 01 | Month | 04 | Day |
Date of IRB
| 2018 | Year | 02 | Month | 19 | Day |
Anticipated trial start date
| 2018 | Year | 02 | Month | 26 | Day |
Last follow-up date
| 2019 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2018 | Year | 01 | Month | 15 | Day |
Last modified on
| 2019 | Year | 04 | Month | 11 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035174
